Company Growth (employees)
Seattle Genetics was founded in 1998 and is headquartered in Bothell, US
Key People at Seattle Genetics
Clay B. Siegall
Co-founder, President , CEO & Chairman
Todd E. Simpson
CFO
Eric Dobmeier
Chief Operating Officer
Vaughn Himes
EVP, Process Sciences and Technical Operations
Chris Boerner
Executive Vice President, Commercial
Jonathan Drachman
Chief Medical Officer; EVP, Research and Development
Seattle Genetics Office Locations
Seattle Genetics has offices in Bothell, Zug and Washington
Bothell, US (HQ)
21717 30th Dr Se
Zug, CH
19 Dammstrasse, Suite 403–406
Seattle Genetics Data and Metrics
Seattle Genetics Financial Metrics
Seattle Genetics's revenue was reported to be $418.1 m in FY, 2016 which is a 24% increase from the previous period.
USD
Revenue (FY, 2016) | 418.1 m |
Revenue growth (FY, 2015 - FY, 2016), % | 24% |
Gross profit (FY, 2016) | 390 m |
Gross profit margin (FY, 2016), % | 93% |
Net income (FY, 2016) | (140.1 m) |
EBIT (FY, 2016) | (142.7 m) |
Market capitalization (19-Jul-2017) | 7.7 b |
Closing share price (19-Jul-2017) | 53.3 |
Cash (31-Dec-2016) | 108.7 m |
Seattle Genetics's current market capitalization is $7.7 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 269.3 m | 286.8 m | 336.8 m | 418.1 m |
Revenue growth, % | 6% | 17% | 24% | |
Cost of goods sold | 13.8 m | 17.5 m | 24.5 m | 28.2 m |
Gross profit | 255.5 m | 269.2 m | 312.3 m | 390 m |
Gross profit Margin, % | 95% | 94% | 93% | 93% |
R&D expense | 379.3 m | |||
General and administrative expense | 139.2 m | |||
Operating expense total | 318.4 m | 346.6 m | 433.3 m | 560.9 m |
EBIT | (62.9 m) | (77.4 m) | (121 m) | (142.7 m) |
EBIT margin, % | (23%) | (27%) | (36%) | (34%) |
Net Income | (62.5 m) | (76.1 m) | (120.5 m) | (140.1 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 64.1 m | 56.9 m | 102.3 m | 108.7 m |
Accounts Receivable | 29.5 m | 39.2 m | 52.9 m | 61.9 m |
Inventories | 27.1 m | 43.5 m | 57 m | 68.1 m |
Current Assets | 437.3 m | 408 m | 771.1 m | 734.6 m |
PP&E | 40.8 m | 46.1 m | 49.6 m | 62.9 m |
Total Assets | 483.9 m | 459 m | 895.1 m | 838.4 m |
Accounts Payable | 120.7 m | |||
Current Liabilities | 99.2 m | 125.9 m | 134.3 m | 148.5 m |
Non-Current Liabilities | 154.5 m | 122.2 m | 74.9 m | 55.8 m |
Total Liabilities | 253.7 m | 248.1 m | 209.2 m | 204.3 m |
Additional Paid-in Capital | 960.4 m | 1 b | 1.6 b | 1.7 b |
Retained Earnings | (730.3 m) | (806.4 m) | (926.9 m) | (1.1 b) |
Total Equity | 230.2 m | 210.8 m | 685.9 m | 634.1 m |
Financial Leverage | 2.1 x | 2.2 x | 1.3 x | 1.3 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (62.5 m) | (76.1 m) | (120.5 m) | (140.1 m) |
Depreciation and Amortization | 8.6 m | 12.5 m | 14.5 m | 18 m |
Accounts Receivable | 3.9 m | (9.7 m) | (14 m) | (9 m) |
Inventories | 10.7 m | (16 m) | (14 m) | (11.2 m) |
Cash From Operating Activities | (1.1 m) | (60 m) | (133.2 m) | (97 m) |
Purchases of PP&E | (22.2 m) | (17.2 m) | (13.4 m) | (27.8 m) |
Cash From Investing Activities | (24.6 m) | 36.6 m | (375.9 m) | 68.2 m |
Cash From Financing Activities | 35.2 m | 16.2 m | 554.4 m | 35.2 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.3 x |
Seattle Genetics Market Value History
Seattle Genetics Job Categories
Seattle Genetics Median Salaries
Source: 47 public H-1B filings from Seattle Genetics
